AU2003260618A8 - Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds - Google Patents

Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Info

Publication number
AU2003260618A8
AU2003260618A8 AU2003260618A AU2003260618A AU2003260618A8 AU 2003260618 A8 AU2003260618 A8 AU 2003260618A8 AU 2003260618 A AU2003260618 A AU 2003260618A AU 2003260618 A AU2003260618 A AU 2003260618A AU 2003260618 A8 AU2003260618 A8 AU 2003260618A8
Authority
AU
Australia
Prior art keywords
pgc
activity
treatment
lateral sclerosis
amyotrophic lateral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003260618A
Other versions
AU2003260618A1 (en
Inventor
Resink Annelies
Fabien Schweighoffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0207783A external-priority patent/FR2841141A1/en
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Publication of AU2003260618A1 publication Critical patent/AU2003260618A1/en
Publication of AU2003260618A8 publication Critical patent/AU2003260618A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003260618A 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds Abandoned AU2003260618A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0207783A FR2841141A1 (en) 2002-06-24 2002-06-24 Treatment of amyotrophic lateral sclerosis, especially to increase neuronal survival time, comprises use of PGC1 modulator, e.g. PGC1 synthesis activator, statin or osteopontin inhibitor
FR02/07783 2002-06-24
US39326102P 2002-07-02 2002-07-02
US60/393,261 2002-07-02
PCT/FR2003/001924 WO2004000313A2 (en) 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Publications (2)

Publication Number Publication Date
AU2003260618A1 AU2003260618A1 (en) 2004-01-06
AU2003260618A8 true AU2003260618A8 (en) 2004-01-06

Family

ID=30001929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003260618A Abandoned AU2003260618A1 (en) 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Country Status (2)

Country Link
AU (1) AU2003260618A1 (en)
WO (1) WO2004000313A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579093A1 (en) * 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating pgc-1.alpha. to treat neurological diseases and disorders
WO2011074690A1 (en) * 2009-12-14 2011-06-23 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
DK2844256T3 (en) 2012-05-02 2023-03-27 Univ Georgetown Treatment of amyotrophic lateral sclerosis with tyrosine kinase inhibitors
CN113384569A (en) * 2013-09-18 2021-09-14 乔治城大学 Treatment of neurodegenerative diseases with fenofibrate and analogs thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU1763201A (en) * 1999-11-10 2001-06-06 Mitokor Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery

Also Published As

Publication number Publication date
AU2003260618A1 (en) 2004-01-06
WO2004000313A3 (en) 2004-04-22
WO2004000313A2 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
IL156595A0 (en) Therapeutic heterocyclic compounds
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EG23458A (en) Set of elements for assemlying structures
HUP0500001A3 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
GB0305150D0 (en) Use of therapeutic compounds
AU2003260618A8 (en) Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
PL359562A1 (en) Interferon for treatment of multiple sclerosis
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2003262141A8 (en) Preperation of desloratatine
AU2002366812A8 (en) Hydrogenation of precursors to thiazolidinedione antihyperglycemics
EP1541548A4 (en) Oxamidination process of carbonyl compounds
EP1420808A4 (en) Treatment of tuberculosis using immunomodulator compounds
GB0014356D0 (en) Treatment of multiple sclerosis
GB0313644D0 (en) Inhibition of infection
GB0222338D0 (en) Surface treatment of concrete
EP1377289A4 (en) Heterocyclic compounds for therapeutic use
EP1451308A4 (en) Therapeutic use of aziridino compounds
AU2003276123A8 (en) Treatment of uveal melanoma
TW459847U (en) Structure of anti-quake fastening piece for stone
IL179528A0 (en) Novel use of peptide compounds for treating amyotrophic lateral sclerosis
TW507567U (en) Improved structure of gloves for shower use
HU0104370D0 (en) Honeyed schnaps of oerseg
TW532128U (en) Improved structure of placement frame for bathtub
TW499941U (en) Novel structure of basin
TW503698U (en) Case dedicated for treatment of animals

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase